The quick read
Elanco’s filed numbers show a business that spent five years losing money and is now generating real profit and accelerating revenue. The stock’s price-to-sales ratio sits at its 71st percentile against its own decade of trading history, meaning the market is paying a premium it has rarely paid before. The open question: the filings justify a better business, but whether they justify this particular price tag depends entirely on how durable the new growth rate turns out to be.
Two numbers that don’t obviously belong together
For four straight fiscal years, Elanco Animal Health lost money. The net margin printed negative every year from 2020 through 2023, meaning the company was burning cents on every dollar it brought in. Today the stock trades at a price-to-sales multiple sitting at its 71st percentile against its own decade of history, according to our data. A business that was deeply unprofitable for most of its public life is now priced as if it belongs among the better years. That tension is the story.
How Elanco got here
Elanco went public in 2018 as Eli Lilly’s animal health spinoff, a mid-sized player in a market dominated by Zoetis. Then it swung big: the Aratana Therapeutics deal closed in July 2019, followed by the Bayer Animal Health acquisition in August 2020 for roughly $6.9 billion, nearly doubling the company’s size overnight. But the debt load that came with those deals weighed on every subsequent income statement. From FY2020 through FY2023, the company posted cumulative losses while trying to integrate two large businesses and service billions in borrowings.
The turn came slowly, then faster. FY2024 was the first year Elanco posted a positive net margin, at 7.6%. A restructuring program called Elanco Ascend, which involves closing facilities in Monheim, Germany, and Kansas City, Kansas, is still running, with tens of millions in charges projected for 2026. The cleanup is not finished. But the direction has changed.
What the most recent quarter actually shows
On August 5, 2026, Elanco reported Q2 2026 revenue of $1.4 billion, up 10% from the same quarter a year earlier. Gross margin, the share of each revenue dollar left after the direct cost of making the product, came in at 58.3%. Adjusted EBITDA, a measure of operating cash generation before interest, taxes, and accounting write-downs, rose more than a fifth year over year.
The growth is coming from two places. The companion animal segment, which sells products for pets, grew double digits, driven by two newer drugs, Zenrelia and Credelio Quattro. The livestock segment also expanded, with the global ruminant portfolio among the faster-growing pieces. That’s a broad-based acceleration, not a single-product story.
The competitive backdrop makes the numbers more interesting. Zoetis, the industry’s largest player, reported U.S. companion animal sales down meaningfully in Q2 2026, with CEO Kristin Peck citing fewer veterinary visits and more price competition. Elanco’s pet health segment grew double digits in the same quarter. Those two readings cannot both reflect a rising tide. One company is taking share from the other. The filings show Elanco’s companion animal segment growing double digits in the same quarter Zoetis reported a decline in that category; readers can weigh what that divergence implies about relative competitive positioning.
The debt that still sits in the room
The Bayer acquisition left a balance sheet that still demands attention. As of June 30, 2026, gross debt stood at $3.7 billion. To put that in kitchen-table terms: imagine a household earning $40,000 a year carrying more than $31,000 on a credit card. The interest alone runs to tens of millions each quarter. The net leverage ratio improved to 3.1 times adjusted EBITDA as of June 30, down half a turn from year-end 2025, and management is targeting further reduction by year-end. Progress is real; the load is still heavy.
Fitch Ratings upgraded Elanco’s issuer rating to BB+ from BB in August 2026, citing balance sheet improvement and more consistent cash generation. BB+ is one notch below investment grade, which means lenders still price in meaningful risk. The October 2025 refinancing extended maturities well into the next decade, so there’s no near-term cliff, but the debt remains a first claim on every dollar of profit the business generates.
What the multiple is asking the business to prove
Our data puts Elanco’s current price-to-sales ratio at its 71st percentile of its own decade of history, and the price-to-earnings ratio at its 75th percentile. In plain terms: the market is paying more for each dollar of Elanco’s sales and earnings than it has for roughly three-quarters of the company’s trading life.
Historically, living at this valuation percentile has coincided with periods of either rapid profit growth or confident expectations of it. The raised full-year 2026 guidance calls for revenue and adjusted EBITDA meaningfully above prior targets, with adjusted EBITDA representing a double-digit increase of approximately 13% at the midpoint. The company has beaten consensus earnings estimates for five consecutive quarters, according to the dossier. The math is improving. The question the multiple poses is whether the improvement is a new baseline or a catch-up from an unusually depressed starting point.
UBS raised its valuation estimate on August 6, 2026, and Citi lifted its estimate into a similar range on August 10, 2026, per the dossier; both firms held constructive ratings on the shares at that time. Weiss Ratings moved in the opposite direction, downgrading the shares on August 20, 2026. The data cannot resolve that disagreement. What it can say is that a P/S ratio at its 71st percentile has, across Elanco’s own history, required sustained revenue growth to stay justified, and the company is currently delivering that growth for the first time since the Bayer deal closed.
Reading the numbers
- Revenue, Q2 2026: $1.4 billion, up 10%. This is the total amount customers paid Elanco in the quarter. A 10% gain means the business is growing about five times faster than the U.S. economy. If a shop that took in $1,000 last spring took in $1,100 this spring, that’s the same rate of change. Source: 10-Q filed for Q2 2026.
- Gross margin, Q2 2026: 58.3%. Of every dollar Elanco collected, about 58 cents remained after paying to make the product. The other 42 cents covered manufacturing. A household analogy: if groceries cost $100 to buy wholesale and sold for $241, the gross margin would be about 58%. Higher margins mean more room to cover overhead and debt service.
- Net leverage: 3.1 times adjusted EBITDA. This is the ratio of net debt to annual operating profit. At 3.1 times, it would take just over three years of all operating profit, with nothing else spent, to retire the debt. A year ago it was higher. The direction matters as much as the level. Source: Q2 2026 filing.
- P/S ratio: 2.6, at the 71st percentile of Elanco’s own decade. The price-to-sales ratio is simply what the market pays for each dollar of annual revenue. At 2.6, investors are paying $2.60 for every $1 of sales, versus a historical median of $1.80. A family that usually pays $180 for a weekly grocery run is now paying $260 for the same cart, betting the contents are better than before. Source: our data, computed from SEC filings and market prices.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- Elanco Q2 2026 press release (PR Newswire, August 5, 2026)
- Q2 2026 10-Q filing summary (StockTitan)
- Analyst valuation estimates and Fitch upgrade (Barchart, August 2026)
- Zoetis Q2 2026 results and competitive context (iTiger)
- Aratana acquisition completion (MarketScreener)
